title: How many patients complete an adequate trial of donepezil?
abstract: Pharmacy claims data were used to evaluate medication adherence among 59 new users of donepezil aged 65 to 94 years. The probability (+/- 95% confidence interval) of a new user continuing donepezil at 90 days was.797 +/-.103 and at 180 days was.627 +/-.124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice.
authors.affiliation: Outcomes Research, Express Scripts, Inc., Maryland Heights, Missouri, 3043, USA. croe@express-scripts.com
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Roe
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Anderson
authors.forename: Barney
authors.initials: B
authors.lastname: Spivack
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy*; D016001:Confidence Intervals; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance / Q000706:statistics & numerical data; D010352:Patient Dropouts / Q000706:statistics & numerical data*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011336:Probability; D014481:United States
chemical_list: D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil